AI & Machine Learning Company in San Diego

Ranges tied to scope, because ML costs are dominated by data readiness, not model choice. A feasibility engagement, meaning data assessment, a baseline model, an honest evaluation against your acceptance threshold, and a written go or no-go, typically runs USD 40,000 to 90,000 over eight to twelve weeks. A production model with a real pipeline, feature engineering, training infrastructure, serving, monitoring, and retraining runs USD 130,000 to 350,000 depending on how much data plumbing has to be built first. A regulated build, meaning a model inside FDA device software jurisdiction or a CLIA-reported workflow, adds design history, verification and validation, subgroup performance characterization, and change-control documentation, and typically lands USD 250,000 to 700,000 and up. Edge deployment adds a quantization, benchmarking, and on-target validation phase, which for a Snapdragon or embedded target is usually four to eight weeks of its own. San Diego rates sit below San Francisco and Seattle but above most of the country because Qualcomm, Illumina, and the defense primes bid for the same engineers. We quote fixed fee against a signed statement of work, and we will tell you when the honest answer is that your data is not ready yet.

If your software has a medical intended use, it is likely a device software function and the AI does not change that. The most useful recent development for San Diego device makers is the FDA final guidance released December 4 2024, titled Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions. A PCCP lets you pre-authorize a defined set of future model modifications as part of the original marketing submission, so planned retraining and performance updates do not each require a new submission. The final version broadened scope from machine learning specifically to all AI-enabled device software functions, and it asks sponsors to account for the characteristics of the intended-use population, including factors like demographic composition and disease severity, and the intended environment of use. Practically, we design the change-control envelope before training starts: what data can be added, what modification types are in scope, what performance thresholds gate a release, and what verification runs on each update. That work is much cheaper up front than retrofitting it after a Dexcom-class or ResMed-class product is already in the field. Your regulatory affairs team owns the submission; we build the engineering evidence it rests on.

The California Genetic Information Privacy Act, SB 41, was signed in October 2021 and took effect January 1 2022. It targets direct-to-consumer genetic testing companies and requires express, separate consent for collection, use, and disclosure of genetic data, disclosure of the policies governing that data, reasonable security practices, consumer access to their own genetic data, deletion of an account and its genetic data on request, and destruction of a biological sample within thirty days when consent is revoked. Penalties reach up to USD 10,000 per violation plus court costs for willful conduct. Even where a San Diego buyer is not a DTC company and is therefore outside the direct scope, GIPA sets the expectation that a due-diligence reviewer or a partner will apply. Separately, the CCPA treats genetic data as sensitive personal information, and SB 1223, signed September 28 2024, added neural data to that same category, which matters for the neurotech and wearable work happening around UC San Diego. Our architecture consequences are concrete: consent state travels with the record, sample and derived-data deletion propagates into training corpora and feature stores rather than stopping at the primary database, and we keep a lineage record showing which consented datasets fed which model version.

This is the most San Diego question there is, and yes, it is a core service line. The workflow starts with an honest target budget: peak memory, sustained power, thermal headroom, and the latency the product actually needs, measured on the real hardware rather than a datasheet. From there we work through post-training quantization to INT8 or INT4, quantization-aware training when post-training loss is unacceptable, structured pruning, and knowledge distillation into a smaller student architecture. We compile through ONNX Runtime, LiteRT, or Core ML for general targets, TensorRT for NVIDIA, and the Qualcomm AI Hub and QNN toolchain when the target is a Snapdragon NPU. The step most teams skip is on-target validation: accuracy measured on the device, not on the training machine, across the temperature and input-quality range the product will see, with a documented degradation curve. We also design the fallback path, because an edge model that silently produces garbage when the sensor is dirty is worse than one that declines to answer. Typical outcome for a vision or signal model is a four to eight times reduction in footprint with a small, measured, and documented accuracy cost you agree to before we ship.

Most San Diego machine learning does not, and knowing why is the useful part. The CPPA regulations that took effect January 1 2026 attach to automated decisionmaking technology used to make a significant decision about a consumer, and the regulation defines that narrowly: financial or lending services, housing, education enrollment or opportunity, employment or independent contracting, and healthcare services. A variant classifier scoring a genome, an RF signal model on a satellite link, a sleep-event scorer, a wildfire risk model on utility hardware, a defect detector on a production line: none of those decide anything about a person in that sense, and we say so in writing rather than leaving you to guess. The models that do land inside are narrower and predictable. A patient-risk stratification model that gates access to a care program, a utilization or coverage model, an underwriting model, a candidate-ranking model. For those the deadline is January 1 2027 for the full ADMT article, including pre-use notice, opt-out, and access rights, and risk assessment documentation for 2026 and 2027 processing goes to the Agency by April 1 2028. What we deliver is a per-model scoping determination written at design time, because the answer depends on how the output is used downstream, not on the architecture, and that distinction is invisible six months later without a record.

Model decay is an operations problem and we treat it as one. Every deployment ships four monitors. Input drift compares the live feature distribution against the training distribution using population stability index or a distributional distance, per feature, with thresholds set during validation. Prediction drift watches the output distribution, which catches upstream breakage that input monitors miss. Data quality watches nulls, ranges, cardinality, and schema changes, because the most common cause of a broken model in production is a changed upstream field, not a shifted concept. Ground-truth monitoring compares predictions against outcomes once labels arrive, on whatever lag your domain has, which for a clinical or genomics workflow can be weeks. Those monitors feed a retraining decision rather than an automatic retrain, because in a regulated San Diego context an unreviewed automatic retrain is a compliance problem. Every model version lives in a registry tied to its training data snapshot, code commit, hyperparameters, and evaluation report, so a rollback is a version pin and an incident review has an actual paper trail. We also run periodic subgroup re-evaluation, since aggregate accuracy can hold steady while performance for one population quietly falls.